Telix Pharmaceuticals

AU: TLX

AU$109.5m market cap

AU$0.73 last close

Telix Pharmaceuticals is a Melbourne-headquartered global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly targeted radiation.

Investment summary

Telix has assembled a portfolio of molecularly targeted radiation therapeutic and imaging products for kidney, prostate and brain cancers. Each product has been validated by clinical studies or compassionate use, reducing development risk. It has acquired its JV partner ANMI in December, giving it full global rights to the illumet investigational prostate cancer imaging kit. It is already commercialising illumet in the US, including through Cardinal Health, and is developing plans for a pivotal study to allow full approval. It has initiated the ZIRCON confirmatory Phase III for kidney cancer imaging agent TLX250; data due H219. The IPAX-1 Phase I/II study of TLX101 therapy in GBM (brain cancer) commenced recruitment in October and is expected to read out in H219. Telix plans to progress TLX591 therapy into Phase III in chemo-naive prostate cancer in H219/H120.

Y/E Dec
Revenue (A$m)
EBITDA (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2016A N/A N/A N/A N/A N/A N/A
2017A 0.4 (6.4) (6.4) (4.98) N/A N/A
2018E 5.0 (13.0) (12.7) (6.21) N/A N/A
2019E 8.4 (17.8) (17.7) (8.33) N/A N/A
Last updated on 20/02/2019
Industry outlook

Big pharma has shown keen interest in MTR products. In 2017 Novartis acquired Advanced Accelerator Applications, the developer of the MTR therapeutic Lutathera, for US$3.9bn. In 2014 Bayer acquired Algeta for ~US$2.6bn; Algeta had developed Xofigo, a therapeutic radiopharmaceutical for prostate cancer. In December Novartis acquired prostate cancer radiopharmaceutical developer Endocyte for US$2.1bn.

Last updated on 20/02/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (A$m) 31.4
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (1.4) (0.7) 46.5
Relative* (5.1) (7.4) 43.4
52-week high/low A$1.0/A$0.5
*% relative to local index
Key management
Christian Behrenbruch CEO
Douglas Cubbin CFO